(Alliance News) - Clinigen Group PLC on Friday unveiled a new contract with biopharmaceutical firm Humanigen that will see the two partner on investigational coronavirus drug Lenzilumab.
Under the exclusive agreement Clinigen will implement a managed access program for the drug, making Lenzilumab available to hospitalised patients with Covid-19 on a case-by-case basis. The program will be available in 16 European countries including France, Spain and Switzerland.
Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.
Shares in the Staffordshire, England-based pharmaceuticals and services provider were up 0.5% at 628.50 pence each in London on Friday morning.
Lenzilumab is an investigational drug which may be beneficial to hospitalised hypoxic Covid-19 patients. It is not currently authorised or approved in any country.
"We are pleased to partner with Humanigen to offer this important treatment option to help address a significant unmet need for hospitalised patients across Europe," said Pete Belden, executive vice president of Services at Clinigen.
"This agreement underlines Clinigen's strength in partnering with biotechnology companies to provide services that enable quicker and broader access to critical medicines."
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
